Emcure Pharmaceuticals Ltd (EMCURE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039308,
    "name": "Emcure Pharma",
    "stock_name": "Emcure Pharma",
    "full_name": "Emcure Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/emcure-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,391.40",
    "chg": -12.85,
    "chgp": "-0.92%",
    "dir": -1,
    "prev_price": "1,404.25",
    "mcapval": "26,376.05 Cr",
    "mcap": "Small Cap",
    "scripcode": 544210,
    "symbol": "EMCURE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE168P01015",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "4.57 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/emcure-pharma-10039308-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Emcure Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marketsmojo-downgrades-emcure-pharma-from-buy-to-hold-on-1-sep-2025-3730730",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharma_mojoScore_3730730.png",
        "date": "2025-11-26 09:46:59",
        "description": "Emcure Pharma’s recent assessment has undergone a revision reflecting nuanced shifts across key evaluation parameters including quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of steady operational performance and evolving market dynamics within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Emcure Pharmaceuticals Trades 1,634,517 Shares, Ranking Among Today's Most Active Equities",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-trades-1634517-shares-ranking-among-todays-most-active-equities-3711316",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_most_active_equities_by_value_3711316.png",
        "date": "2025-11-18 10:00:32",
        "description": "Emcure Pharmaceuticals Ltd has become one of the most actively traded stocks today, with a volume of over 1.6 million shares. Despite a decline in its stock price, investor participation has increased, and the stock remains above its 200-day moving average, indicating ongoing market interest."
      },
      {
        "title": "How has been the historical performance of Emcure Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-emcure-pharma-3695832",
        "imagepath": "",
        "date": "2025-11-13 00:41:59",
        "description": "Answer:\nEmcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years.\n\nBreakdown:\nIn the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.9..."
      },
      {
        "title": "Are Emcure Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharma-latest-results-good-or-bad-3693277",
        "imagepath": "",
        "date": "2025-11-12 19:36:16",
        "description": "Emcure Pharmaceuticals has reported its financial results for the quarter ended September 2025, showcasing a notable operational performance. The company achieved net sales of ₹2,269.82 crores, reflecting a sequential growth of 8.06% compared to the previous quarter. This growth is accompanied by a year-on-year revenue increase of 13.38%, indicating a robust sales trajectory. \n\nIn terms of profitability, Emcure's net profit reached ₹243.46 crores, which is a 17.64% increase from the prior quarter and a significant 25.13% rise year-on-year. The operating margin, excluding other income, expanded to 20.95%, marking the highest level in the last eight quarters. This improvement in margins suggests effective cost management and operational efficiency, which are critical in the capital-intensive pharmaceutical sector.\n\nThe company also demonstrated strong capital efficiency, with a return on equity of 15.50% and ..."
      },
      {
        "title": "Emcure Pharmaceuticals Q2 FY26: Strong Quarter Marred by Premium Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/emcure-pharmaceuticals-q2-fy26-strong-quarter-marred-by-premium-valuation-concerns-3690801",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_quaterlyResult_3690801.png",
        "date": "2025-11-11 20:19:19",
        "description": "Emcure Pharmaceuticals Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹26,706 crores, delivered a robust performance in Q2 FY26, posting consolidated net profit of ₹243.46 crores—a sequential improvement of 17.64% and a year-on-year surge of 25.13%. However, the stock declined 3.90% on November 11, 2025, trading at ₹1,371.95, as investors grappled with the company's expensive valuation multiples and concerns over long-term growth sustainability."
      },
      {
        "title": "Why is Emcure Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-emcure-pharma-fallingrising-3687445",
        "imagepath": "",
        "date": "2025-11-11 00:26:43",
        "description": "As of 10-Nov, Emcure Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 1,427.65, reflecting an increase of 66.5 points or 4.89%. The stock has shown strong performance today, outperforming its sector by 3.84% and has been on a consecutive gain streak for the last three days, with a total return of 7.71% over that period. The stock opened with a gain of 2.04% today and reached an intraday high of Rs 1464.7, indicating positive momentum. Additionally, the company has demonstrated high management efficiency with a return on capital employed (ROCE) of 20.99% and a low debt to EBITDA ratio of 0.53 times, which supports its ability to service debt effectively. Institutional investors have also increased their stake by 1.96%, indicating growing confidence in the company’s fundamentals.\n\nIn the broader market context, Emcure Pharmaceuticals has outperformed the Sensex over the past week, w..."
      },
      {
        "title": "Emcure Pharmaceuticals Hits Day High with 7.01% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-hits-day-high-with-701-surge-in-stock-price-3685817",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_priceRelatedfactors_3685817.png",
        "date": "2025-11-10 12:33:08",
        "description": "Emcure Pharmaceuticals has experienced notable activity, achieving consecutive gains over three days and outperforming its sector. The stock is currently trading above key moving averages and is nearing its 52-week high, indicating a strong position within the pharmaceuticals and biotechnology industry."
      },
      {
        "title": "Is Emcure Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-emcure-pharma-technically-bullish-or-bearish-3674654",
        "imagepath": "",
        "date": "2025-11-06 08:31:35",
        "description": "As of 4 November 2025, the technical trend for Emcure Pharma has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are showing mildly bearish signals. The RSI has no signal on both the weekly and monthly time frames, suggesting a lack of momentum. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts...."
      },
      {
        "title": "Emcure Pharmaceuticals Faces Mixed Technical Trends Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-market-volatility-3674828",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_technicaldot_3674828.png",
        "date": "2025-11-06 08:21:17",
        "description": "Emcure Pharmaceuticals has recently revised its evaluation amid current market dynamics. The stock is priced at 1325.00, reflecting a slight decline. Over the past year, Emcure has faced challenges with a negative return, contrasting with the Sensex's positive performance. Technical indicators present a mixed outlook for the company."
      }
    ],
    "total": 333,
    "sid": "10039308",
    "stock_news_url": "https://www.marketsmojo.com/news/emcure-pharmaceuticals-10039308"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "01-Dec-2025",
      "details": "Intimation of schedule of Analyst/ Investor Meeting(s)",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Search And Seizure/ Inspection Operation Conducted By The Goods & Service Tax Department Mumbai Maharashtra.",
      "datetime": "27-Nov-2025",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding search and seizure/ inspection operation conducted by Good & Service Tax Department Mumbai Maharashtra at offices of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer",
      "datetime": "21-Nov-2025",
      "details": "Mr. Chetan Sharma (FCS:8352) has submitted his resignation from post of company Secretary and Compliance Officer & Key Managerial Personnel of the Company with effect from close of business hours on November 24 2025 to pursue opportunities outside the organization.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Emcure Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals

2025-11-26 09:46:59

Emcure Pharma’s recent assessment has undergone a revision reflecting nuanced shifts across key evaluation parameters including quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of steady operational performance and evolving market dynamics within the Pharmaceuticals & Biotechnology sector.

Emcure Pharmaceuticals Trades 1,634,517 Shares, Ranking Among Today's Most Active Equities

2025-11-18 10:00:32

Emcure Pharmaceuticals Ltd has become one of the most actively traded stocks today, with a volume of over 1.6 million shares. Despite a decline in its stock price, investor participation has increased, and the stock remains above its 200-day moving average, indicating ongoing market interest.

How has been the historical performance of Emcure Pharma?

2025-11-13 00:41:59

Answer: Emcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years. Breakdown: In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.9...

Are Emcure Pharma latest results good or bad?

2025-11-12 19:36:16

Emcure Pharmaceuticals has reported its financial results for the quarter ended September 2025, showcasing a notable operational performance. The company achieved net sales of ₹2,269.82 crores, reflecting a sequential growth of 8.06% compared to the previous quarter. This growth is accompanied by a year-on-year revenue increase of 13.38%, indicating a robust sales trajectory. In terms of profitability, Emcure's net profit reached ₹243.46 crores, which is a 17.64% increase from the prior quarter and a significant 25.13% rise year-on-year. The operating margin, excluding other income, expanded to 20.95%, marking the highest level in the last eight quarters. This improvement in margins suggests effective cost management and operational efficiency, which are critical in the capital-intensive pharmaceutical sector. The company also demonstrated strong capital efficiency, with a return on equity of 15.50% and ...

Emcure Pharmaceuticals Q2 FY26: Strong Quarter Marred by Premium Valuation Concerns

2025-11-11 20:19:19

Emcure Pharmaceuticals Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹26,706 crores, delivered a robust performance in Q2 FY26, posting consolidated net profit of ₹243.46 crores—a sequential improvement of 17.64% and a year-on-year surge of 25.13%. However, the stock declined 3.90% on November 11, 2025, trading at ₹1,371.95, as investors grappled with the company's expensive valuation multiples and concerns over long-term growth sustainability.

Why is Emcure Pharma falling/rising?

2025-11-11 00:26:43

As of 10-Nov, Emcure Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 1,427.65, reflecting an increase of 66.5 points or 4.89%. The stock has shown strong performance today, outperforming its sector by 3.84% and has been on a consecutive gain streak for the last three days, with a total return of 7.71% over that period. The stock opened with a gain of 2.04% today and reached an intraday high of Rs 1464.7, indicating positive momentum. Additionally, the company has demonstrated high management efficiency with a return on capital employed (ROCE) of 20.99% and a low debt to EBITDA ratio of 0.53 times, which supports its ability to service debt effectively. Institutional investors have also increased their stake by 1.96%, indicating growing confidence in the company’s fundamentals. In the broader market context, Emcure Pharmaceuticals has outperformed the Sensex over the past week, w...

Emcure Pharmaceuticals Hits Day High with 7.01% Surge in Stock Price

2025-11-10 12:33:08

Emcure Pharmaceuticals has experienced notable activity, achieving consecutive gains over three days and outperforming its sector. The stock is currently trading above key moving averages and is nearing its 52-week high, indicating a strong position within the pharmaceuticals and biotechnology industry.

Is Emcure Pharma technically bullish or bearish?

2025-11-06 08:31:35

As of 4 November 2025, the technical trend for Emcure Pharma has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are showing mildly bearish signals. The RSI has no signal on both the weekly and monthly time frames, suggesting a lack of momentum. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts....

Emcure Pharmaceuticals Faces Mixed Technical Trends Amid Market Volatility

2025-11-06 08:21:17

Emcure Pharmaceuticals has recently revised its evaluation amid current market dynamics. The stock is priced at 1325.00, reflecting a slight decline. Over the past year, Emcure has faced challenges with a negative return, contrasting with the Sensex's positive performance. Technical indicators present a mixed outlook for the company.

View All News